SCHEMBL6843709

SCHEMBL6843709

O=C(O)c1ccc2c(c1)C(Cl)(Cl)c1cc(C(=O)O)ccc1-2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.47
SRD5A2 P31213 4/20 0.46
TTR P02766 2/20 0.46
SRD5A1 P18405 3/20 0.44
PTPRC P08575 2/20 0.44
TP53 P04637 1/20 0.44
PDK2 Q15119 1/20 0.44
POLB P06746 2/20 0.43
KDM4E B2RXH2 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
CA4 P22748 1/20 0.43
CA6 P23280 1/20 0.43
PTGS2 P35354 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5846588 0.83 TSHR (0.50) TSHRSRD5A2TTRSRD5A1PTPRC
SCHEMBL29371850 0.79 RARB (0.46) TSHRSRD5A2TTRPTPRCTP53
SCHEMBL21439836 0.79 RARB (0.46) TSHRSRD5A2TTRPTPRCTP53
Hydrochloric Acid SCHEMBL28484832 0.78 RARB (0.45) TSHRSRD5A2TTRPTPRCTP53
SCHEMBL28842566 0.78 PDK2 (0.46) TSHRSRD5A2TTRPTPRCTP53
SCHEMBL6990696 0.77 PDK2 (0.56) PTPRCTP53PDK2KDM4ECA12
SCHEMBL28598017 0.77 SRD5A2 (0.56) TSHRSRD5A2TTRSRD5A1PTPRC
SCHEMBL5846670 0.75 PDK2 (0.55) SRD5A2TTRSRD5A1PTPRCPDK2
SCHEMBL2456262 0.75 PDK2 (0.55) SRD5A2TTRSRD5A1PTPRCPDK2
SCHEMBL31128645 0.75 POLB (0.47) TSHRSRD5A2TTRPTPRCTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use GUILFORD PHARMACEUTICALS, INC. 2004-04-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040063785-A1 Symmetrically disubstituted aromatic compounds and pharmaceutical compositions for inhibiting poly (ADP-ribose) glycohydrolase, and methods for their use PARG, PARP1, PARP11 TSHR 4699/4885SRD5A2 1817/4885TTR 3454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.